Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

The burden of taking a daily dose of PrEP might soon be lifted. According to updated CDC guidelines, bi-monthly injectable PrEP is expected to receive FDA approval by February. The injectable ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

One year ago, the United States approved a new injectable drug that prevents HIV. After successful clinical trials, long-acting cabotegravir was found to be almost 100 per cent effective at preventing ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Please provide your email address to receive an email when new articles are posted on . Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...